Cochrane · systematic review · CD009355
Role of chemotherapy additional to high‐dose methotrexate for primary central nervous system lymphoma (PCNSL)
Bergner, N, Monsef, I, Illerhaus, G, et al. · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
4
No studies
1
Included studies
NR
No studies 1 · 20%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 80%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Cytarabine plus high‐dose methotrexate versus high‐dose methotrexate alone in patients with primary CNS lymphoma
Population: patients with primary CNS lymphoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality (median 3 years) Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone | HR 0.65 [0.38, 1.13] | 1 study · 79 participants | Moderate |
Progression/relapse (median 3 years) Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone | HR 0.54 [0.31, 0.92] | 1 study · 79 participants | Moderate |
Treatment‐related mortality Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone | RR 3.08 [0.33, 28.32] | 1 study · 79 participants | Moderate |
Serious adverse events Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone | no estimate extracted | NR | No studies |
Infections (grade 3 to 4) Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone | RR 9.23 [1.23, 69.47] | 1 study · 79 participants | Moderate |